The University of Chicago Header Logo

Peter O'Donnell

Concepts (484)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pharmacogenetics
45
2026
474
13.820
Why?
Pharmacogenomic Testing
18
2026
119
7.750
Why?
Carcinoma, Transitional Cell
25
2026
158
6.680
Why?
Precision Medicine
18
2026
512
4.400
Why?
Urologic Neoplasms
20
2026
82
4.260
Why?
Urinary Bladder Neoplasms
22
2026
403
3.960
Why?
Drug-Related Side Effects and Adverse Reactions
7
2022
220
2.710
Why?
Decision Support Systems, Clinical
6
2025
135
2.470
Why?
Antibodies, Monoclonal, Humanized
19
2026
1105
2.220
Why?
Cisplatin
19
2026
578
2.190
Why?
Drug Prescriptions
6
2025
161
2.160
Why?
Antineoplastic Agents
24
2025
2386
2.110
Why?
Patient Portals
3
2025
36
2.040
Why?
Antibodies, Monoclonal
17
2026
1422
2.020
Why?
Prescription Drugs
3
2025
42
1.950
Why?
Pharmacogenomic Variants
4
2021
46
1.950
Why?
Neoplasms
13
2025
3382
1.650
Why?
Perioperative Care
7
2026
199
1.620
Why?
Practice Patterns, Physicians'
6
2025
669
1.550
Why?
Immunoconjugates
3
2026
140
1.530
Why?
Antimetabolites, Antineoplastic
7
2024
246
1.450
Why?
Humans
132
2026
98799
1.390
Why?
Clinical Decision-Making
5
2021
306
1.280
Why?
Biomarkers, Tumor
8
2025
1786
1.250
Why?
Capecitabine
7
2024
103
1.240
Why?
Aged
52
2026
21986
1.230
Why?
Middle Aged
58
2026
29642
1.190
Why?
Prospective Studies
15
2025
4837
1.140
Why?
Decision Support Techniques
2
2021
193
1.140
Why?
Polymorphism, Single Nucleotide
10
2025
2577
1.140
Why?
Aged, 80 and over
30
2026
7461
1.130
Why?
Anesthesiology
2
2022
172
1.100
Why?
Genotype
11
2023
1895
1.090
Why?
Male
63
2026
47475
1.080
Why?
Health Knowledge, Attitudes, Practice
3
2026
608
1.030
Why?
Female
62
2026
51997
1.010
Why?
Adult
45
2026
29698
0.990
Why?
Patient Acceptance of Health Care
2
2020
315
0.910
Why?
Antineoplastic Agents, Immunological
5
2024
238
0.850
Why?
Genomics
5
2022
914
0.850
Why?
Cardiovascular Agents
2
2015
62
0.840
Why?
Urothelium
5
2023
67
0.820
Why?
Hematopoietic Stem Cell Transplantation
7
2016
979
0.800
Why?
Point-of-Care Systems
3
2019
155
0.730
Why?
Referral and Consultation
1
2026
419
0.730
Why?
Antineoplastic Combined Chemotherapy Protocols
13
2026
2666
0.710
Why?
Tramadol
1
2022
14
0.710
Why?
Patient Care Team
1
2025
318
0.710
Why?
Kidney Neoplasms
5
2021
556
0.700
Why?
Hepatic Veno-Occlusive Disease
2
2012
20
0.680
Why?
Busulfan
2
2012
41
0.670
Why?
Germ-Line Mutation
4
2020
404
0.660
Why?
Anesthetics
1
2021
51
0.660
Why?
Platinum
5
2023
68
0.660
Why?
Pain Management
2
2021
198
0.650
Why?
B7-H1 Antigen
9
2022
333
0.640
Why?
Rheumatology
1
2021
47
0.630
Why?
Patient Education as Topic
2
2026
419
0.630
Why?
Analgesics
1
2021
131
0.630
Why?
Anesthesia
1
2022
177
0.610
Why?
Carcinoma, Renal Cell
3
2021
384
0.590
Why?
Medication Adherence
1
2020
130
0.570
Why?
Drug Labeling
2
2017
44
0.560
Why?
Information Dissemination
1
2019
135
0.550
Why?
Drug Therapy
2
2018
67
0.550
Why?
Deoxycytidine
2
2026
218
0.540
Why?
Pharmacology, Clinical
1
2018
9
0.540
Why?
Quinazolines
2
2016
222
0.530
Why?
Cardiovascular Diseases
2
2015
824
0.520
Why?
Benzamides
4
2025
260
0.520
Why?
Follow-Up Studies
12
2026
4049
0.520
Why?
Medical Order Entry Systems
1
2017
29
0.510
Why?
Surveys and Questionnaires
5
2026
3058
0.500
Why?
Germ Cells
2
2022
137
0.500
Why?
Patient Care
1
2018
100
0.490
Why?
Inpatients
3
2025
371
0.490
Why?
Vidarabine
3
2012
107
0.490
Why?
Prostatic Neoplasms, Castration-Resistant
3
2025
121
0.490
Why?
Receptor, Fibroblast Growth Factor, Type 3
1
2016
22
0.480
Why?
Fluorouracil
2
2023
543
0.480
Why?
Genome, Human
3
2019
834
0.480
Why?
Analgesics, Opioid
1
2021
546
0.480
Why?
Receptor, ErbB-3
1
2016
19
0.470
Why?
Critical Care
1
2019
464
0.450
Why?
Physician-Patient Relations
2
2019
584
0.450
Why?
Physician's Role
1
2017
183
0.450
Why?
Clinical Medicine
1
2015
27
0.440
Why?
Cytochrome P-450 CYP2D6
3
2022
53
0.440
Why?
Clinical Trials, Phase II as Topic
4
2014
168
0.440
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2015
82
0.440
Why?
Collagen Type I
1
2015
75
0.440
Why?
Snake Venoms
2
2015
10
0.440
Why?
Quality of Life
7
2024
1904
0.440
Why?
Patient Selection
3
2018
725
0.430
Why?
Phenylthiohydantoin
2
2025
58
0.430
Why?
Academic Medical Centers
2
2015
416
0.420
Why?
Genetic Predisposition to Disease
5
2025
2588
0.420
Why?
Programmed Cell Death 1 Receptor
5
2022
201
0.420
Why?
Pyrroles
2
2015
166
0.410
Why?
Nectins
3
2022
8
0.410
Why?
Transplantation Conditioning
4
2014
389
0.400
Why?
Cystectomy
3
2026
125
0.400
Why?
Treatment Outcome
19
2025
9806
0.390
Why?
Cardiology
1
2015
125
0.390
Why?
Neovascularization, Pathologic
1
2015
356
0.390
Why?
Ambulatory Care
2
2014
203
0.380
Why?
Program Development
1
2014
141
0.380
Why?
Indoles
2
2015
340
0.380
Why?
Inflammation
1
2019
1134
0.380
Why?
Biomarkers, Pharmacological
1
2012
21
0.370
Why?
Pain
4
2024
417
0.360
Why?
Hematologic Neoplasms
4
2016
384
0.360
Why?
Stomach Neoplasms
1
2015
321
0.360
Why?
Mutation
6
2020
4443
0.350
Why?
Peptides
1
2015
671
0.350
Why?
Chicago
6
2026
1520
0.350
Why?
Young Adult
7
2025
7598
0.340
Why?
Protein Kinase Inhibitors
1
2016
642
0.340
Why?
Dose-Response Relationship, Drug
6
2024
1949
0.340
Why?
Pharmaceutical Preparations
1
2012
109
0.330
Why?
Neoplasm Staging
7
2021
2087
0.330
Why?
Patient Reported Outcome Measures
3
2024
337
0.320
Why?
Kidney Failure, Chronic
2
2016
451
0.320
Why?
Patient Safety
4
2023
237
0.320
Why?
Cell Adhesion Molecules
2
2022
186
0.320
Why?
Prognosis
12
2020
4139
0.320
Why?
Antibodies, Neoplasm
1
2010
87
0.310
Why?
Drug Delivery Systems
1
2012
202
0.310
Why?
Hemoglobinopathies
1
2010
9
0.310
Why?
Carcinoma
3
2021
442
0.310
Why?
Neoplasm Metastasis
7
2024
1102
0.300
Why?
Kidney Medulla
1
2010
79
0.300
Why?
Drug Resistance, Neoplasm
3
2011
671
0.300
Why?
BK Virus
1
2009
23
0.300
Why?
Neoplasm Recurrence, Local
1
2017
1538
0.290
Why?
United States
7
2025
8387
0.290
Why?
Polyomavirus Infections
1
2009
29
0.290
Why?
Urinary Bladder
4
2026
263
0.290
Why?
Brain Neoplasms
1
2015
845
0.290
Why?
Tumor Virus Infections
1
2009
83
0.290
Why?
Carboplatin
6
2016
331
0.290
Why?
Pyrimidines
3
2018
416
0.290
Why?
Hematuria
1
2009
53
0.290
Why?
Warfarin
2
2019
109
0.280
Why?
Neoplasm Invasiveness
7
2026
583
0.270
Why?
Disease Susceptibility
1
2009
225
0.270
Why?
Breast Neoplasms
2
2020
3303
0.270
Why?
Genetic Variation
3
2014
1460
0.270
Why?
Genetic Testing
4
2019
610
0.270
Why?
Anemia, Sickle Cell
1
2010
158
0.260
Why?
Risk Assessment
3
2021
2604
0.250
Why?
Nitriles
2
2025
172
0.250
Why?
Kidney Diseases
1
2009
313
0.240
Why?
Models, Genetic
1
2012
1006
0.240
Why?
Cohort Studies
4
2019
3242
0.230
Why?
Sulfotransferases
1
2025
17
0.230
Why?
Genotyping Techniques
2
2018
72
0.230
Why?
Transplantation, Homologous
7
2020
1029
0.230
Why?
Risk Factors
5
2021
6295
0.230
Why?
Kidney
1
2011
1126
0.230
Why?
Androstenes
1
2025
42
0.230
Why?
Sirolimus
1
2006
181
0.220
Why?
Oncologists
1
2025
43
0.220
Why?
Randomized Controlled Trials as Topic
4
2019
995
0.210
Why?
Genome-Wide Association Study
9
2025
1863
0.210
Why?
Polymorphism, Genetic
3
2015
832
0.210
Why?
Neuroendocrine Tumors
1
2006
158
0.210
Why?
Peripheral Nervous System Diseases
1
2025
94
0.210
Why?
Tertiary Care Centers
2
2016
131
0.200
Why?
Angiogenesis Inhibitors
2
2016
281
0.200
Why?
Survival Analysis
6
2023
1530
0.200
Why?
Medical Oncology
2
2022
426
0.200
Why?
Sleep Initiation and Maintenance Disorders
1
2024
54
0.190
Why?
Adolescent
8
2025
10168
0.190
Why?
Insurance Coverage
1
2025
159
0.190
Why?
Insurance, Health
1
2025
192
0.190
Why?
Neutropenia
1
2023
211
0.190
Why?
Patient Participation
1
2025
251
0.190
Why?
Adenine Nucleotides
2
2014
57
0.190
Why?
Alemtuzumab
3
2012
91
0.190
Why?
Proprotein Convertase 9
1
2023
29
0.190
Why?
Arabinonucleosides
2
2014
37
0.190
Why?
Receptors, Glucocorticoid
1
2024
145
0.190
Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2023
90
0.190
Why?
Thrombocytopenia
1
2023
194
0.180
Why?
Hospitalization
2
2019
993
0.180
Why?
Fenretinide
1
2002
2
0.180
Why?
Omeprazole
1
2022
11
0.180
Why?
Succinylcholine
1
2022
14
0.180
Why?
Ceramides
1
2002
36
0.180
Why?
Hydralazine
1
2022
22
0.180
Why?
Serine Endopeptidases
1
2023
154
0.180
Why?
Oxycodone
1
2022
35
0.170
Why?
Sulfonamides
2
2016
352
0.170
Why?
Lymphocytes
3
2010
461
0.170
Why?
Chemotherapy, Adjuvant
3
2026
527
0.170
Why?
Triple Negative Breast Neoplasms
1
2024
218
0.170
Why?
Patient Readmission
1
2025
441
0.170
Why?
Muscles
1
2021
179
0.160
Why?
Practice Guidelines as Topic
2
2018
1116
0.160
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.160
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
28
0.160
Why?
Disease-Free Survival
6
2021
1196
0.150
Why?
Pyrazines
1
2020
98
0.150
Why?
Research
2
2019
258
0.150
Why?
Clinical Trials as Topic
2
2016
1128
0.150
Why?
Non-alcoholic Fatty Liver Disease
1
2022
198
0.150
Why?
Drug Recalls
1
2019
12
0.150
Why?
Codeine
1
2019
12
0.140
Why?
Health Plan Implementation
1
2019
62
0.140
Why?
CREB-Binding Protein
1
2018
17
0.140
Why?
E1A-Associated p300 Protein
1
2018
16
0.140
Why?
Predictive Value of Tests
2
2021
1792
0.140
Why?
Phenotype
3
2019
2673
0.140
Why?
Pilot Projects
2
2019
978
0.140
Why?
Survival Rate
3
2018
2057
0.140
Why?
Evidence-Based Medicine
1
2021
483
0.140
Why?
Acute Kidney Injury
2
2014
361
0.140
Why?
Gene Expression Regulation, Neoplastic
3
2021
1400
0.140
Why?
Response Evaluation Criteria in Solid Tumors
4
2021
61
0.140
Why?
Tumor Burden
1
2019
330
0.140
Why?
Infusions, Intravenous
3
2017
403
0.130
Why?
Neoadjuvant Therapy
2
2026
477
0.130
Why?
Electronic Health Records
2
2025
456
0.130
Why?
Program Evaluation
1
2019
349
0.130
Why?
Guidelines as Topic
1
2019
169
0.130
Why?
Vinca Alkaloids
2
2025
4
0.130
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2002
445
0.130
Why?
Tumor Microenvironment
2
2022
621
0.130
Why?
Abdominal Neoplasms
1
2017
38
0.130
Why?
Radiosurgery
1
2021
352
0.130
Why?
Standard of Care
1
2017
71
0.120
Why?
Lymphocytes, Tumor-Infiltrating
1
2018
168
0.120
Why?
Organoplatinum Compounds
2
2019
95
0.120
Why?
User-Computer Interface
1
2017
195
0.120
Why?
Social Perception
1
2017
93
0.120
Why?
Drug Therapy, Computer-Assisted
1
2016
9
0.120
Why?
Disease Management
1
2019
378
0.120
Why?
Safety
1
2017
138
0.120
Why?
Health Personnel
1
2019
259
0.120
Why?
Tissue Donors
1
2020
581
0.120
Why?
Chemoradiotherapy
1
2018
337
0.120
Why?
Benzodioxoles
1
2015
15
0.110
Why?
Liver
3
2022
1231
0.110
Why?
Anticoagulants
1
2019
486
0.110
Why?
Hospital Mortality
1
2019
533
0.110
Why?
Attitude to Health
1
2017
217
0.110
Why?
Case-Control Studies
1
2020
2017
0.110
Why?
Transcription Factor RelA
1
2015
39
0.110
Why?
Universities
2
2013
166
0.110
Why?
Vascular Cell Adhesion Molecule-1
1
2015
58
0.110
Why?
5' Untranslated Regions
1
2015
52
0.110
Why?
Forecasting
1
2016
298
0.110
Why?
Communication
1
2019
457
0.110
Why?
G(M2) Ganglioside
1
2015
3
0.110
Why?
Tay-Sachs Disease
1
2015
6
0.110
Why?
Response Elements
1
2015
68
0.110
Why?
Tunica Intima
1
2015
62
0.110
Why?
Area Under Curve
2
2014
341
0.110
Why?
Survivors
1
2016
211
0.110
Why?
Drug Administration Schedule
3
2026
837
0.110
Why?
Ureter
1
2016
81
0.110
Why?
Fatal Outcome
1
2015
295
0.110
Why?
Immunotherapy
2
2020
831
0.110
Why?
Maximum Tolerated Dose
2
2017
265
0.110
Why?
Epilepsies, Myoclonic
1
2015
40
0.100
Why?
Data Interpretation, Statistical
1
2016
312
0.100
Why?
Nomograms
1
2014
34
0.100
Why?
Attitude of Health Personnel
1
2019
688
0.100
Why?
Exome
1
2014
150
0.100
Why?
Kidney Transplantation
2
2016
944
0.100
Why?
Genetic Markers
1
2014
471
0.100
Why?
Radiography
1
2015
763
0.100
Why?
CD8-Positive T-Lymphocytes
1
2018
701
0.100
Why?
Total Quality Management
1
2013
31
0.100
Why?
Liver Neoplasms
2
2017
840
0.100
Why?
Receptors, Cell Surface
1
2014
291
0.100
Why?
Kaplan-Meier Estimate
3
2026
909
0.100
Why?
Muscle Neoplasms
1
2013
16
0.090
Why?
Software
1
2017
698
0.090
Why?
Endothelium, Vascular
1
2015
440
0.090
Why?
Endonucleases
1
2012
22
0.090
Why?
Workflow
1
2013
88
0.090
Why?
Fanconi Anemia
1
2012
10
0.090
Why?
Genetics, Medical
1
2013
51
0.090
Why?
DNA Repair
1
2014
363
0.090
Why?
Delivery of Health Care
1
2017
483
0.090
Why?
Biopsy
2
2016
1226
0.090
Why?
Lymphocyte Depletion
1
2012
103
0.090
Why?
Atherosclerosis
1
2015
273
0.090
Why?
Models, Statistical
1
2016
602
0.090
Why?
Combined Modality Therapy
3
2024
1754
0.090
Why?
Disease Progression
3
2016
1621
0.090
Why?
Blood Glucose
1
2016
915
0.090
Why?
High-Throughput Nucleotide Sequencing
3
2022
588
0.090
Why?
Time Factors
3
2016
5586
0.090
Why?
Fibroblasts
1
2015
767
0.090
Why?
Decision Making
1
2017
691
0.090
Why?
Melphalan
1
2011
98
0.090
Why?
Graft vs Host Disease
2
2012
382
0.090
Why?
Databases, Factual
1
2016
1102
0.080
Why?
Biomedical Research
2
2013
477
0.080
Why?
T-Lymphocytes
2
2022
1335
0.080
Why?
HLA Antigens
1
2012
239
0.080
Why?
Population Groups
1
2010
44
0.080
Why?
Metabolic Clearance Rate
1
2010
118
0.080
Why?
Chromosomes, Human, X
1
2011
57
0.080
Why?
Stem Cell Transplantation
1
2012
196
0.080
Why?
Population Surveillance
1
2012
218
0.080
Why?
Inhibitory Concentration 50
1
2010
61
0.080
Why?
Drug Combinations
1
2010
202
0.080
Why?
Cell Line, Transformed
1
2010
153
0.080
Why?
Graft Rejection
2
2016
1189
0.080
Why?
Cell Line
5
2011
2484
0.070
Why?
Tumor Suppressor Protein p53
1
2012
470
0.070
Why?
Anthracyclines
1
2009
31
0.070
Why?
Postoperative Complications
2
2016
2719
0.070
Why?
Down-Regulation
1
2010
529
0.070
Why?
DNA
1
2014
1274
0.070
Why?
Antineoplastic Agents, Alkylating
1
2009
136
0.070
Why?
Haplotypes
1
2010
657
0.070
Why?
Creatinine
1
2009
315
0.070
Why?
Immune Complex Diseases
1
2008
19
0.070
Why?
Neutrophil Infiltration
1
2008
32
0.070
Why?
Intercellular Adhesion Molecule-1
1
2008
78
0.070
Why?
Cell Proliferation
2
2010
1801
0.060
Why?
Fatigue
2
2022
187
0.060
Why?
DNA-Binding Proteins
1
2012
1275
0.060
Why?
Genetics, Population
1
2010
451
0.060
Why?
Neurons
1
2015
1634
0.060
Why?
Diabetes Mellitus
1
2013
815
0.060
Why?
Incidence
1
2010
1798
0.060
Why?
Immunosuppressive Agents
1
2010
1021
0.060
Why?
Bridged-Ring Compounds
1
2025
16
0.060
Why?
Kidney Function Tests
2
2016
124
0.050
Why?
Mice, Inbred C57BL
3
2022
3628
0.050
Why?
Taxoids
1
2025
127
0.050
Why?
Tumor Necrosis Factor-alpha
1
2008
712
0.050
Why?
Androgen Receptor Antagonists
1
2024
21
0.050
Why?
Ovarian Neoplasms
1
2011
829
0.050
Why?
Lymph Node Excision
1
2026
238
0.050
Why?
Magnetic Resonance Imaging
1
2016
3622
0.050
Why?
Indazoles
2
2016
65
0.050
Why?
Head and Neck Neoplasms
1
2011
1091
0.050
Why?
Models, Biological
1
2011
1806
0.050
Why?
Receptors, Androgen
1
2024
126
0.050
Why?
Hyperparathyroidism
1
2003
66
0.050
Why?
Dihydrouracil Dehydrogenase (NADP)
1
2023
28
0.050
Why?
Asialoglycoprotein Receptor
1
2023
2
0.050
Why?
Proprotein Convertases
1
2023
27
0.050
Why?
Phthalazines
1
2023
60
0.050
Why?
Leucine
1
2022
57
0.050
Why?
Glomerular Filtration Rate
2
2016
304
0.050
Why?
Parathyroidectomy
1
2003
88
0.050
Why?
Clinical Trials, Phase I as Topic
2
2014
154
0.050
Why?
Pharmacists
1
2022
41
0.050
Why?
Alleles
2
2017
1163
0.050
Why?
Cell Line, Tumor
3
2016
2913
0.050
Why?
Adrenal Insufficiency
1
2022
23
0.050
Why?
Sphingolipids
1
2002
21
0.040
Why?
Vaccines, Synthetic
1
2022
61
0.040
Why?
Reproducibility of Results
2
2021
2799
0.040
Why?
Morpholines
1
2002
64
0.040
Why?
Age Factors
2
2020
1976
0.040
Why?
Antibody Formation
1
2022
173
0.040
Why?
Drug Synergism
1
2002
317
0.040
Why?
Diet, High-Fat
1
2022
144
0.040
Why?
Immunity, Cellular
1
2022
187
0.040
Why?
Ligands
1
2023
492
0.040
Why?
Cholesterol, LDL
1
2023
250
0.040
Why?
Piperazines
1
2023
308
0.040
Why?
Receptors, G-Protein-Coupled
1
2022
176
0.040
Why?
DNA Damage
1
2023
400
0.040
Why?
Gene Fusion
1
2021
41
0.040
Why?
beta Catenin
1
2022
269
0.040
Why?
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
1
2021
67
0.040
Why?
Hodgkin Disease
1
2001
144
0.040
Why?
Risk
2
2012
662
0.040
Why?
Bone Marrow Transplantation
1
2001
287
0.040
Why?
Cholesterol
1
2022
377
0.040
Why?
Tumor Cells, Cultured
1
2002
1029
0.040
Why?
Blood Transfusion
1
2001
179
0.040
Why?
Prostatic Neoplasms
1
2011
1846
0.040
Why?
Retrospective Studies
3
2024
11104
0.040
Why?
Antibodies, Viral
1
2022
342
0.040
Why?
Vaccination
1
2022
328
0.040
Why?
Cell Survival
1
2002
1018
0.040
Why?
Protein-Tyrosine Kinases
1
2021
305
0.040
Why?
Double-Blind Method
1
2023
1793
0.040
Why?
Allografts
1
2020
221
0.040
Why?
Hematopoiesis
1
2020
187
0.040
Why?
Gene Expression
2
2015
1322
0.040
Why?
Blood Platelets
1
2019
153
0.030
Why?
Mice
3
2022
12762
0.030
Why?
Histone Deacetylase Inhibitors
1
2018
109
0.030
Why?
Proto-Oncogene Proteins
1
2021
687
0.030
Why?
Retreatment
1
2017
106
0.030
Why?
Internationality
1
2017
80
0.030
Why?
Single-Blind Method
1
2017
160
0.030
Why?
Amino Acid Substitution
1
2018
336
0.030
Why?
BCG Vaccine
1
2017
44
0.030
Why?
Social Discrimination
1
2016
7
0.030
Why?
Remission Induction
1
2018
764
0.030
Why?
DNA Mutational Analysis
1
2018
554
0.030
Why?
National Institutes of Health (U.S.)
1
2017
140
0.030
Why?
Drug Screening Assays, Antitumor
1
2016
87
0.030
Why?
Employment
1
2016
67
0.030
Why?
Immunoglobulins, Intravenous
1
2016
67
0.030
Why?
Cholesterol, Dietary
1
2015
27
0.030
Why?
Europe
1
2016
360
0.030
Why?
Transplants
1
2016
43
0.030
Why?
E-Selectin
1
2015
31
0.030
Why?
Child
3
2016
7771
0.030
Why?
Carotid Artery Injuries
1
2015
22
0.030
Why?
Chemotaxis, Leukocyte
1
2015
39
0.030
Why?
Receptors, Antigen, T-Cell
1
2018
454
0.030
Why?
Receptors, LDL
1
2015
54
0.030
Why?
Glycoside Hydrolase Inhibitors
1
2015
1
0.030
Why?
1-Deoxynojirimycin
1
2015
3
0.030
Why?
RNA Polymerase II
1
2015
63
0.030
Why?
Protein Interaction Mapping
1
2015
81
0.030
Why?
Netrin Receptors
1
2014
7
0.030
Why?
Lentivirus
1
2015
44
0.030
Why?
Administration, Oral
1
2016
677
0.030
Why?
Primary Cell Culture
1
2015
84
0.030
Why?
Hyperglycemia
1
2016
187
0.030
Why?
Microsomes, Liver
1
2014
48
0.030
Why?
Transgenes
1
2015
173
0.030
Why?
Transduction, Genetic
1
2015
160
0.030
Why?
Transplant Recipients
1
2016
182
0.030
Why?
Plasmids
1
2015
275
0.030
Why?
Social Support
1
2016
246
0.030
Why?
Recurrence
2
2011
1274
0.030
Why?
Reference Standards
1
2014
147
0.030
Why?
Ireland
1
2013
13
0.020
Why?
Nephrectomy
1
2016
291
0.020
Why?
Cluster Analysis
1
2014
401
0.020
Why?
Genetic Vectors
1
2015
425
0.020
Why?
Societies, Medical
1
2017
687
0.020
Why?
Multicenter Studies as Topic
1
2013
195
0.020
Why?
Animals
3
2022
29045
0.020
Why?
Transplantation Chimera
1
2012
84
0.020
Why?
United States Department of Defense
1
2011
4
0.020
Why?
Endothelial Cells
1
2015
502
0.020
Why?
Immunohistochemistry
1
2016
1818
0.020
Why?
Promoter Regions, Genetic
1
2015
979
0.020
Why?
Early Termination of Clinical Trials
1
2011
16
0.020
Why?
Graft Survival
1
2016
999
0.020
Why?
Nerve Tissue Proteins
1
2015
529
0.020
Why?
Contrast Media
1
2016
1014
0.020
Why?
Orchiectomy
1
2011
63
0.020
Why?
Students
1
2013
197
0.020
Why?
Transplantation, Autologous
2
2003
398
0.020
Why?
Action Potentials
1
2015
612
0.020
Why?
Genes, X-Linked
1
2011
39
0.020
Why?
Insulin
1
2016
1226
0.020
Why?
Diarrhea
1
2011
180
0.020
Why?
Computational Biology
1
2014
620
0.020
Why?
Transcription, Genetic
1
2015
1136
0.020
Why?
Cells, Cultured
1
2015
2859
0.020
Why?
Proportional Hazards Models
1
2012
925
0.020
Why?
Mice, Knockout
1
2015
2217
0.020
Why?
Patient Compliance
1
2011
247
0.020
Why?
Lymphoma, Non-Hodgkin
1
2011
262
0.020
Why?
Herpesvirus 4, Human
1
2010
127
0.020
Why?
Laparoscopy
1
2016
800
0.020
Why?
Adenosine Triphosphate
1
2010
320
0.020
Why?
Quality Improvement
1
2013
538
0.020
Why?
Macrophage-1 Antigen
1
2008
18
0.020
Why?
Severity of Illness Index
1
2014
2025
0.020
Why?
Neoplasm Proteins
1
2011
553
0.020
Why?
Cell Differentiation
1
2015
1656
0.020
Why?
Receptors, IgG
1
2008
70
0.020
Why?
Diabetes Mellitus, Type 2
1
2016
1293
0.020
Why?
Registries
1
2013
1133
0.020
Why?
Bone Marrow Cells
1
2008
269
0.020
Why?
Cell Adhesion
1
2008
421
0.020
Why?
Transcription Factors
1
2015
1724
0.020
Why?
Physicians
1
2013
687
0.010
Why?
Gene Expression Profiling
1
2011
1572
0.010
Why?
Leukemia, Myeloid, Acute
1
2011
850
0.010
Why?
Biomarkers
1
2011
2026
0.010
Why?
Baltimore
1
2001
42
0.010
Why?
Longitudinal Studies
1
2001
1305
0.010
Why?
O'Donnell's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (484)
Explore
_
Co-Authors (92)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_